HC Wainwright Reaffirms “Buy” Rating for Insmed (NASDAQ:INSM)

Insmed (NASDAQ:INSM)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Monday, Benzinga reports. They currently have a $220.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 127.30% from the company’s previous close. HC Wainwright also issued estimates for Insmed’s FY2027 earnings at $1.63 EPS.

Several other research analysts have also issued reports on INSM. Wolfe Research lowered shares of Insmed from an “outperform” rating to a “peer perform” rating in a research note on Monday. Guggenheim dropped their price target on shares of Insmed from $207.00 to $205.00 and set a “buy” rating for the company in a research note on Friday, August 7th. Barclays dropped their price target on shares of Insmed from $237.00 to $207.00 and set an “overweight” rating for the company in a research note on Wednesday, September 30th. Evercore restated an “outperform” rating and issued a $170.00 price objective on shares of Insmed in a report on Friday, August 7th. Finally, Morgan Stanley restated an “overweight” rating and issued a $218.00 price objective on shares of Insmed in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $200.30.

Insmed Stock Performance

Insmed stock opened at $96.79 on Monday. The business’s 50-day simple moving average is $120.16 and its 200 day simple moving average is $119.10. Insmed has a 12-month low of $90.39 and a 12-month high of $212.75. The company has a current ratio of 3.72, a quick ratio of 3.40 and a debt-to-equity ratio of 0.74.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.61. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%. The firm had revenue of $425.49 million during the quarter, compared to analyst estimates of $395.50 million. During the same period last year, the company earned ($1.70) earnings per share. The company’s revenue was up 296.1% on a year-over-year basis. On average, equities analysts predict that Insmed will post -1.84 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, COO Roger Adsett sold 239,850 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $133.27, for a total value of $31,964,809.50. Following the completion of the sale, the chief operating officer owned 98,744 shares in the company, valued at approximately $13,159,612.88. This represents a 70.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director David Brennan sold 25,000 shares of the company’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total value of $3,100,000.00. Following the completion of the sale, the director owned 39,238 shares of the company’s stock, valued at $4,865,512. This represents a 38.92% decrease in their position. The SEC filing for this sale provides additional information. 2.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Insmed

Institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp bought a new position in Insmed during the 2nd quarter worth about $139,966,000. Railway Pension Investments Ltd acquired a new stake in shares of Insmed in the 2nd quarter valued at about $64,473,000. Sei Investments Co. raised its stake in shares of Insmed by 56.8% in the 1st quarter. Sei Investments Co. now owns 1,395,794 shares of the biopharmaceutical company’s stock valued at $228,239,000 after purchasing an additional 505,624 shares during the period. Alberta Investment Management Corp acquired a new stake in shares of Insmed in the 4th quarter valued at about $35,945,000. Finally, SEB Asset Management AB bought a new stake in shares of Insmed in the first quarter valued at about $27,075,000.

Key Insmed News

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and maintained a $220 price target, implying substantial upside from recent trading levels. The firm also slightly raised its FY2027 EPS estimate to $1.63 from $1.62. Insmed’s Buy Rating Reaffirmed at HC Wainwright
• Positive Sentiment: Investors purchased 8,177 call options on Tuesday, more than triple the average volume of 2,676 contracts. The unusually high call activity may indicate increased speculative interest or expectations for a rebound, although options positioning does not guarantee future gains.
• Neutral Sentiment: Analyst coverage remains divided: HC Wainwright is bullish, while Wolfe Research moved to a more neutral stance. This disagreement may contribute to elevated volatility as investors reassess Insmed’s valuation and growth outlook. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: Wolfe Research downgraded Insmed from Outperform to Peer Perform, removing a bullish endorsement and likely pressuring the stock. The downgrade was highlighted as the main catalyst behind the shares’ decline. Insmed Shares Fall After Wolfe Research Downgrade

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company’s research and development activities center on pulmonary and inflammatory conditions, with an emphasis on diseases that have limited treatment options.

Insmed’s principal commercial product is ARIKAYCE liposomal, an inhaled formulation of amikacin used with a combination antibacterial regimen to treat refractory Mycobacterium avium complex lung disease in certain adult patients.